The recent decision in the Bayer vs FTC case contains positive lessons and some points of caution for the industry, notably around what you need to substantiate claims and why FTC is not going away, says Steve Mister, President and CEO of the CRN.
The Bayer vs FTC case in the US District Court of New Jersey is full of lessons, including what does and does not constitute ‘competent and reliable scientific evidence’, and the importance of having experts who know the space.
UPDATED: NPA calls decision a "win for the industry and consumers"
The hotly anticipated decision in the dispute between Bayer and the US Federal Trade Commission over claims in support of Phillips’ Colon Health is in, with a judge ruling in favor of the company.
